Market Flux Event
Syndax IPF Drug Axatilimab Fails Phase 2 MAXPIRe Trial, Ending Pulmonary Fibrosis Program
Read this in the Market Flux appSyndax Pharmaceuticals announced topline results from its MAXPIRe Phase 2 trial showing that axatilimab failed to meet the primary endpoint of annualized rate of forced vital capacity decline in patients with idiopathic pulmonary fibrosis. The miss ends Syndax's IPF program entirely, despite axatilimab demonstrating a safety profile comparable to placebo in the trial.
Shares of Syndax fell sharply on the news, with Seeking Alpha reporting the stock plummeted following the announcement. The failure removes what the company had described as a transformative pipeline expansion opportunity, as positive data would have supported axatilimab's mechanism across several fibrotic indications.
Investors and analysts are now directing attention to Syndax's remaining pipeline. The company's core value is anchored in revumenib, its menin inhibitor, and the axatilimab chronic graft-versus-host disease franchise, where additional data readouts are expected in late 2026 and the first half of 2028.
© AI-generated summary is provided by Market Flux
Sources
- BioStocks$SNDX Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis – Trial did not meet the primary endpoint of annualized rate of FVC decline
- BPharmCatalyst$SNDX reported that its Phase 2 MAXPIRe study of axatilimab in idiopathic pulmonary fibrosis failed its primary FVC endpoint, ending the IPF program despite a placebo-like safety profile. While losing a pipeline expansion route, core value remains anchored in revumenib and the axatilimab cGVHD franchise, which has additional readouts expected in late 2026 and 1H 2028. $SNDX $TRAX $CRVO $PCSA $SXTC $TXG $TCRT $PASG $CTNM $MDCX For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section
- Seeking AlphaSyndax plummets as IPF asset axatilimab fails in phase 2 trial